Gibson Christopher
SEC CIK 1856369 · EDGAR
BoughtSold
Most active insiders at RXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Borgeson Blake | Dir | — | $4.10M |
| 2 | Gibson Christopher | Dir | — | $3.84M |
| 3 | Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| 4 | Taylor Ben R | CFO | — | $157.7K |
| 5 | Bumpus Namandje | Dir | — | $28.1K |
| 6 | Michor Franziska | Dir | — | — |
| 7 | Hallett David | CSO | — | — |
| 8 | Dar Zavain | Dir | — | — |
| 9 | Li Dean Y | Dir | — | — |
| 10 | Sun Elaine D | Dir | — | — |
Transactions 305
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-05 | 2024-04-03+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $8.93 | -80.0K | 938.5K | -8% | -$714.4K |
| DMI | 2024-04-05 | 2024-04-03+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +50.0K | 25.0K | New | $0 |
| DMI | 2024-04-05 | 2024-04-03+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $8.93 | -50.0K | 0 | -100% | -$446.5K |
| DI | 2024-04-01 | 2024-03-28 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 25.0K | New | $0 |
| D | 2024-04-01 | 2024-03-28 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $10.10 | -40.0K | 1.04M | -4% | -$404.0K |
| D | 2024-04-01 | 2024-03-28 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 1.08M | -2% | $0 |
| DI | 2024-04-01 | 2024-03-28 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $10.10 | -25.0K | 0 | -100% | -$252.5K |
| DMI | 2024-03-08 | 2024-03-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.55 | -25.0K | 0 | -100% | -$288.8K |
| DMI | 2024-03-08 | 2024-03-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 4,000 | New | $0 |
| D | 2024-03-08 | 2024-03-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 1.10M | -0.9% | $0 |
| DM | 2024-03-08 | 2024-03-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $4.42 | +39.9K | 1.14M | +4% | +$176.4K |
| D | 2024-03-08 | 2024-03-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.86 | -36.3K | 1.11M | -3% | -$430.7K |
| D | 2024-03-08 | 2024-03-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 1.11M | +0.9% | $0 |
| 2024-02-16 | 2024-02-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $12.43 | -11.1K | 1.10M | -1.0% | -$138.6K | |
| DM | 2024-02-13 | 2024-02-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +344.6K | 1.12M | +44% | $0 |
| D | 2024-02-13 | 2024-02-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $10.09 | -3,233 | 1.12M | -0.3% | -$32.6K |
| D | 2024-02-09 | 2024-02-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.22 | -48.3K | 774.7K | -6% | -$445.1K |
| D | 2024-02-09 | 2024-02-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 823.0K | +4% | +$77.5K |
| D | 2024-02-09 | 2024-02-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 791.7K | -1% | $0 |
| D | 2024-02-09 | 2024-02-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 801.7K | +1% | $0 |
| DMI | 2024-01-05 | 2024-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 4,000 | New | $0 |
| DMI | 2024-01-05 | 2024-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.51 | -25.0K | 0 | -100% | -$237.7K |
| D | 2024-01-05 | 2024-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 801.3K | +1% | $0 |
| D | 2024-01-05 | 2024-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 791.3K | -1% | $0 |
| D | 2024-01-05 | 2024-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.49 | -30.9K | 791.7K | -4% | -$292.8K |
| D | 2024-01-05 | 2024-01-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 822.6K | +4% | +$77.5K |
| D | 2023-12-08 | 2023-12-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 851.2K | +4% | +$77.5K |
| D | 2023-12-08 | 2023-12-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 819.9K | -1% | $0 |
| D | 2023-12-08 | 2023-12-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.49 | -59.8K | 791.3K | -7% | -$448.1K |
| D | 2023-12-08 | 2023-12-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 829.9K | +1% | $0 |
| D | 2023-11-17 | 2023-11-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 846.8K | +1% | $0 |
| D | 2023-11-17 | 2023-11-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 836.8K | -1% | $0 |
| D | 2023-11-17 | 2023-11-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $7.18 | -16.9K | 819.9K | -2% | -$121.4K |
| D | 2023-11-03 | 2023-11-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 874.0K | +4% | +$77.5K |
| D | 2023-11-03 | 2023-11-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $5.20 | -37.2K | 836.8K | -4% | -$193.3K |
| DMI | 2023-11-03 | 2023-11-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| DMI | 2023-11-03 | 2023-11-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $5.12 | -25.0K | 0 | -100% | -$127.9K |
| D | 2023-10-18 | 2023-10-16 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 842.7K | -1% | $0 |
| D | 2023-10-18 | 2023-10-16 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 852.7K | +1% | $0 |
| D | 2023-10-06 | 2023-10-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 902.5K | +4% | +$77.5K |
| D | 2023-10-06 | 2023-10-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.21 | -59.8K | 842.7K | -7% | -$431.1K |
| D | 2023-09-19 | 2023-09-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 881.3K | +1% | $0 |
| D | 2023-09-19 | 2023-09-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 871.3K | -1% | $0 |
| DMI | 2023-09-08 | 2023-09-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.83 | -25.0K | 0 | -100% | -$220.8K |
| DMI | 2023-09-08 | 2023-09-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| D | 2023-09-08 | 2023-09-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 905.1K | +4% | +$77.5K |
| D | 2023-09-08 | 2023-09-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.78 | -33.8K | 871.3K | -4% | -$296.5K |
| 2023-08-17 | 2023-08-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $9.19 | -16.9K | 873.8K | -2% | -$155.4K | |
| D | 2023-08-11 | 2023-08-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 890.7K | -1% | $0 |
| D | 2023-08-11 | 2023-08-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 900.7K | +1% | $0 |
| DM | 2023-08-04 | 2023-08-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $4.42 | +39.9K | 955.7K | +4% | +$176.4K |
| DM | 2023-08-04 | 2023-08-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $13.04 | -65.0K | 894.8K | -7% | -$847.9K |
| D | 2023-07-21 | 2023-07-20 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 915.8K | -1% | $0 |
| D | 2023-07-21 | 2023-07-20 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 925.8K | +1% | $0 |
| D | 2023-07-14 | 2023-07-12 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 947.6K | +3% | +$77.5K |
| DM | 2023-07-14 | 2023-07-12 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $13.14 | -31.8K | 915.8K | -3% | -$418.0K |
| DMI | 2023-07-14 | 2023-07-12 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| DMI | 2023-07-14 | 2023-07-12 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.77 | -25.0K | 0 | -100% | -$294.2K |
| D | 2023-06-16 | 2023-06-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 916.4K | -1% | $0 |
| D | 2023-06-16 | 2023-06-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 926.4K | +1% | $0 |
| D | 2023-06-09 | 2023-06-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 972.8K | +3% | +$77.5K |
| D | 2023-06-09 | 2023-06-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.05 | -56.4K | 916.4K | -6% | -$510.7K |
| 2023-05-17 | 2023-05-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $5.60 | -11.7K | 941.6K | -1% | -$65.3K | |
| DMI | 2023-05-05 | 2023-05-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $4.90 | -25.0K | 0 | -100% | -$122.6K |
| DM | 2023-05-05 | 2023-01-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.3K | 956.4K | +1% | $0 |
| DM | 2023-05-05 | 2023-01-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -19.0K | 955.0K | -2% | $0 |
| D | 2023-05-05 | 2023-05-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 986.3K | +3% | +$77.5K |
| D | 2023-05-05 | 2023-05-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $4.71 | -33.1K | 953.2K | -3% | -$155.8K |
| DMI | 2023-05-05 | 2023-05-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| DMA | 2023-04-28 | 2022-01-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +75.5K | 601.3K | +14% | $0 |
| DMA | 2023-04-28 | 2022-04-25+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -57.0K | 582.8K | -9% | $0 |
| DA | 2023-04-28 | 2022-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.39 | -18.5K | 582.8K | -3% | -$136.7K |
| DM | 2023-04-07 | 2023-04-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.60 | -53.3K | 946.7K | -5% | -$351.7K |
| D | 2023-04-07 | 2023-04-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 960.0K | +3% | +$77.5K |
| D | 2023-04-07 | 2023-04-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 928.8K | -1% | $0 |
| D | 2023-03-15 | 2023-03-13 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -3,000 | 938.8K | -0.3% | $0 |
| D | 2023-03-15 | 2023-03-13 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +3,000 | 941.8K | +0.3% | $0 |
| DMI | 2023-03-10 | 2023-03-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 20.0K | New | $0 |
| D | 2023-03-10 | 2023-03-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 953.8K | -1% | $0 |
| DMI | 2023-03-10 | 2023-03-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.10 | -25.0K | 0 | -100% | -$202.5K |
| D | 2023-03-10 | 2023-03-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +93.8K | 1.03M | +10% | +$232.5K |
| DM | 2023-03-10 | 2023-03-08+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.04 | -85.9K | 963.8K | -8% | -$690.8K |
| D | 2023-03-06 | 2023-03-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.92 | -18.5K | 940.9K | -2% | -$146.5K |
| DMI | 2023-03-06 | 2023-03-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2023-03-06 | 2023-03-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 956.4K | +2% | $0 |
| DMI | 2023-03-06 | 2023-03-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.91 | -2,500 | 0 | -100% | -$19.8K |
| 2023-02-17 | 2023-02-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $8.44 | -1,346 | 940.9K | -0.1% | -$11.4K | |
| D | 2023-02-03 | 2023-02-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 960.8K | +2% | $0 |
| D | 2023-02-03 | 2023-02-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $8.55 | -1,382 | 942.3K | -0.1% | -$11.8K |
| DM | 2023-02-03 | 2023-02-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +417.9K | 932.6K | +81% | $0 |
| DMI | 2023-02-03 | 2023-02-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $9.21 | -2,500 | 0 | -100% | -$23.0K |
| DMI | 2023-02-03 | 2023-02-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2023-02-03 | 2023-02-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $9.22 | -18.5K | 942.3K | -2% | -$170.6K |
| DM | 2023-01-06 | 2022-04-25+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -57.0K | 570.8K | -9% | $0 |
| D | 2023-01-06 | 2023-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 544.3K | +4% | $0 |
| D | 2023-01-06 | 2023-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.39 | -18.5K | 525.8K | -3% | -$136.7K |
| DMI | 2023-01-06 | 2023-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DMI | 2023-01-06 | 2023-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.38 | -2,500 | 0 | -100% | -$18.5K |
| D | 2022-12-02 | 2022-12-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 601.5K | +5% | +$77.5K |
| DM | 2022-12-02 | 2022-12-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.02 | -37.2K | 582.8K | -6% | -$335.8K |
Purchase Sale Sale after option exercise All abbreviations